Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
Kamal S. Saini, Carlo Lanza, Marco Romano, Evandro de Azambuja, Javier Cortés, Begoña de las Heras, Javier de Castro, Monika Lamba Saini, Sibylle Loibl, Giuseppe Curigliano, Chris Twelves, Manuela Leone, Mrinal M. Patnaik
Abstract
Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
Topics & Concepts
CoagulopathyInflammationMedicineRepurposingImmune systemCoronavirus disease 2019 (COVID-19)Immune DysfunctionImmunologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBioinformaticsInternal medicinePathologyDiseaseBiologyInfectious disease (medical specialty)EcologyOutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19COVID-19 and healthcare impacts